Purpose

The purpose of this study is to analyze tumor tissue samples from patients of Native American identity with prostate cancer. By examining these samples, researchers hope to understand how different genes in your tumor can influence treatment decisions, how your cancer progresses and the outcome of your cancer.

Condition

Eligibility

Eligible Ages
Between 18 Years and 100 Years
Eligible Sex
Male
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Written informed consent signed and dated by the patient prior to the performance of any study-specific procedures, sampling, or analyses. - At least 18 years-of-age at the time of signature of the informed consent form (ICF). - Patients who self-identify as Native American. - Patients with a pathologically proven diagnosis of PC (any stage). - Availability of most recent archived tumor samples.

Exclusion Criteria

  • Patients not of Native American descent or identity. - Patient does not have archival tissue available.

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
Native American Group 150 patients will be assigned in this group.
  • Other: Bio-specimen Collection
    Tissue samples will be taken from existing archived collections and sent for further analysis.
  • Other: Blood Draw
    Blood samples will be collected within the first year of enrollment.

Recruiting Locations

OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma 73117
Contact:
Adanma Ayanambakkam, MD
405-271-4022
Adanma-Ayanambakkam@ouhsc.edu

More Details

NCT ID
NCT06960798
Status
Recruiting
Sponsor
University of Oklahoma

Study Contact

Lead Onco Nurse
405-271-8777
SCC-IIT-Office@ouhsc.edu

Detailed Description

This study aims to establish a comprehensive database of Native American (NA) patients diagnosed with prostate cancer (PC), focusing on an in-depth characterization of the genomic landscape. Archived tumor tissue collected at screening and peripheral blood samples obtained within the first year of enrollment will serve as the basis for comprehensive molecular analyses. Whole exome sequencing (WES) and whole transcriptome sequencing (RNA-seq) will be performed to characterize and delineate the genomic and transcriptomic landscape of the study cohort. The study will initially enroll participants at the Stephenson Cancer Center, with planned expansion to additional sites across Oklahoma and, subsequently, to other institutions across the United States. Oversight will be maintained by the Tribal Institutional Review Board and an independent Community Advisory Board to ensure cultural appropriateness, transparency, and sustained community engagement throughout the research process. The overarching objective is to generate insights that will inform the development of personalized treatment strategies in the future.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.